Today’s AI Top Pick: BKV

7/29/2026 · Quality Squeeze screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Measured daily model accuracy · BKV62%277 resolved forecasts · 45d window · verify →

Today's pick · Quality SqueezeBKVBUY NOW8.6 / 107/29/2026

BKV is the cleanest quality-squeeze setup on the board right now. It combines the highest fundamental score (8/8) with a full-house bullish signal (kronos_probability 1.0, near_term 1.0) AND — crucially — it is NOT at the top of its range. Position-in-21bar-range is 14.6% (1h), 5.8% (4h), and 5.9% (1d), with drawdown of −13.4% from the recent high and RSI at 31.7 (oversold). That is the textbook 'buy the dip in a quality name' geometry the screen is designed to find. Everything else on the board with a bullish tape is either extended at the range top (LRN, DUOL, INSP, FRPT all at 100%) or has a landmine headline (see below). Multi-timeframe forecasts all confirm to the upside: 1h fc_short/mid/long = +19.1/+16.3/+15.5%, 4h = +19.4/+23.9/+21.0%, 1d = +3.7/+12.3/+7.6%. There is no timeframe pointing down. Fundamentals reinforce: PE 7.1, PEG 0.69, fwdPE 11.9, profit margin 27.9%, ROE 15.9%, D/E 0.57, salesYoY +52.4%, EPS next year +27.4%. Analyst recom of 1.23 (strong buy) with a 43.8% target upside is the strongest analyst signal in the pool that is not undercut by a fresh downgrade. The news check is clean and supportive: Simply Wall St (7/26) called it '28% undervalued,' Susquehanna reiterated Positive (7/21) — the small PT trim to $35 is still meaningful upside from $23.70 — and StockStory named BKV the 'best of the bunch' in upstream gas E&P Q1 earnings. Compare to the next-strongest forecast names: PEGA (fc +64% on 1d) just dropped 16.9% on customers delaying AI purchases and got a 'Reasons to Avoid' piece; TTD got a Rating Downgrade note titled 'Wounds Are Unlikely To Heal Well'; INSP got a UBS Sell initiation; LYFT has an active short-seller warning. BKV has none of that. Today is the right entry, not later, because you are buying an oversold pullback (RSI 31.7, pos-in-range <15% across intraday timeframes) in a name where the multi-TF forecast has already re-inflected up (+15–24% expected across 4h/1d bars). If you wait for a breakout, you give up the asymmetric part of the trade — the low position-in-range is precisely why the risk/reward is favorable right now.

Entry zone

$23.20 – $23.90 (scale into current $23.70; add on any dip toward $23.00)

Stop loss

$21.80 (below the 21-bar low; ~8% risk, protects against a break of the oversold structure)

First target

$27.00 (+14%, fills gap toward mid-range and near intraday fc_short/mid magnitude)

Longer target

$31–$33 (+31–39%, aligns with Susquehanna's $35 PT and 43.8% analyst target upside)

Risks

Short float 20.18% — cuts both ways; a squeeze helps but a break of $21.80 could accelerate down as shorts press
Natural gas price sensitivity: BKV is an upstream E&P, so a further NatGas selloff (already implied by −13.4% drawdown) could extend pain before the forecast plays out
1wk timeframe was not provided — cannot fully confirm the long-term weekly trend is intact; a weekly breakdown would invalidate the setup
Analyst PT was just cut by Susquehanna (from prior to $35) — direction of estimate revisions is not yet inflecting up
Small-mid cap ($2.57B) — thin liquidity can amplify volatility on any macro energy tape move

Honorable mentions

PSIXDeepest oversold in the pool (RSI 30.65, pos-in-range 0–10%, DD −28% daily), enormous forecasted rebound (+95–152% mid/long on 1d), ROE 75.7%, PE 6.3, salesYoY +38.6%, target upside 152.2%, and a fresh CEO appointment 7/27. Held back from #1 only because the 1wk forecast is still negative (−18 to −36%) — the weekly downtrend is not yet broken, so best treated as a BUY_PULLBACK / speculative add rather than the safest single buy today.

DOCSFull bullish stack (prob 1.0, near-term 0.8), massive daily forecast (+37.7/+83.6/+73.8%), reasonable position-in-range (~42–52%), best-in-class margins (gross 89%, profit 30.4%), D/E 0.01, and clean news. Sits behind BKV on fundamental_score (4.5 vs 8) and BKV is more oversold.

Full ranking (23)

#	Symbol	Verdict	Score	Read
1	BKV	BUY NOW	8.6	All-TF bullish (prob 1.0), oversold RSI 31.7, pos-in-range <15%, fund score 8, PE 7.1, clean supportive news — the textbook quality-squeeze entry.
2	PSIX	BUY PULLBACK	7.6	Deep-value squeeze with +95–152% intraday forecasts and new CEO, but 1wk fc still −18 to −36% keeps it a speculative add rather than the safest buy.
3	DOCS	BUY NOW	7.2	Prob 1.0, 1d fc +37/+83/+74%, elite margins (30% net) and near-zero debt, mid-range entry — high-quality confirming setup.
4	UPWK	BUY NOW	6.8	fwdPE 5.63, PEG 0.43, 4h/1d fc +42/+55% — deep-value tape with prob 1.0, mildly capped by 'cheap for a reason' narrative.
5	CRMD	BUY PULLBACK	6.4	Oversold (RSI 35.7, DD −16%) with 1d fc +30% mid, ROE 65.6%, profit margin 45%, RBC Outperform reiterated.
6	PEGA	WAIT	6.0	Forecast magnitudes are massive (+64% mid on 1d) but 7/23 −16.9% drop on AI purchase delays + fresh 'Avoid' note materially undercuts the thesis.
7	FOXA	BUY PULLBACK	5.6	Prob 1.0 and constructive setup but pos-in-range 99.6% on daily — needs pullback; 1wk fc turns negative (−24 to −30%).
8	TTD	WAIT	5.4	Enormous long-horizon fc (+225–278% wk) offset by fresh SeekingAlpha rating downgrade and −31% weekly drawdown momentum.
9	LYFT	WAIT	5.2	PE 2.17 and prob 0.8 but near-term forecasts mildly negative and active short-seller warning is a real overhang.
10	DDD	WAIT	4.8	FDA clearance is a positive catalyst but prob 0.0 and negative 1d/4h forecasts contradict the news pop.
11	TDC	WAIT	4.6	Oversold with modest positive short-term fc and ROE 117%, but prob 0.0 and mid/long forecasts turn negative.
12	FRPT	WAIT	4.4	JPM raised PT to $72 but daily pos-in-range 100% and short/mid forecasts negative — chasing the top.
13	GCT	WAIT	4.2	Fund score 7.5 and PE 10 but prob 0.0 and all mid/long forecasts negative (−17 to −34%).
14	LRN	AVOID	4.0	Pos-in-range 100% across all TFs with prob 0.2 and 4h fc −17% — classic 'don't chase the top.'
15	DUOL	AVOID	3.9	At 100% of range on every TF with negative short/mid forecasts, fwdPE 40 and −18% target downside.
16	DLO	AVOID	3.7	Prob 0.0 with every TF forecast negative (−8 to −17%) despite strong fundamentals — tape says wait.
17	INSP	AVOID	3.5	UBS just initiated Sell with $39 PT, product recalls, target upside −1% — forecast noise not enough to override.
18	PATH	AVOID	3.2	Prob 0.0, all forecasts negative, pos-in-range 99–100% on daily/weekly — extended and rolling over.
19	ABEO	AVOID	2.6	Insider selling twice in July, all forecasts negative, operMargin −637%, prob 0.0.
20	EVER	AVOID	2.2	Forecasts brutally negative (1h −37%, 4h −29%, 1wk −33%) with insider selling; screen pass is a mirage.
21	ONDS	AVOID	1.8	43.9% short float, dilution headlines, PS 46, fwdPE null, all long-horizon forecasts −38 to −52%.
22	SEZL	AVOID	1.6	Forecasts across all TFs deeply negative (−32 to −60%) after +147% YTD run — mean reversion trap.
23	QTTB	AVOID	1.2	Every mid/long forecast −50 to −78%, +604% one-year run, short interest rising — reversion is imminent.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord